Selank and the GABA system: the evidence, and the result that did not reproduce

Published August 28, 2026 · Artemis Labs

Selank’s proposed mechanism is that it modulates the GABA system, the brain’s main inhibitory signaling network and the same system benzodiazepines act on. Three lines of published evidence support it: the behavioral resemblance to benzodiazepines, a binding study describing Selank as a positive allosteric modulator of GABA binding, and a rat experiment in which Selank changed the expression of dozens of neurotransmission genes. One result cuts hard against it. When the same research group ran the same 84-gene panel on human neuroblastoma cells, they “found no changes in the mRNA levels of the genes studied under the effect of Selank.” Both results are published, and any honest account of the mechanism carries both.

Key findings

• Binding study: “It was shown that Selank affect the [3H]GABA binding as a positive allosteric modulator” — and that it “is able to block the modulatory activity of Diazepam and Olanzapine” (PMID 30255741).
• In rat frontal cortex, one and three hours after administration: “We found significant changes in the expression of 45 genes 1 h after the administration of the compounds,” with 22 still changed at three hours (PMID 26924987).
• In human IMR-32 neuroblastoma cells, same 84-gene panel, same group: “We found no changes in the mRNA levels of the genes studied under the effect of Selank” (PMID 28293190).
• That second study did find an interaction: combining GABA with Selank “led to nearly complete suppression of changes in expression of genes in which mRNA levels changed under the effect of GABA.”

What “positive allosteric modulator” means

A receptor can be switched on directly by the molecule it evolved to receive. It can also be nudged by a second molecule that binds somewhere else on the same receptor and changes how well the first one works. The second kind is an allosteric modulator — positive if it strengthens the response, negative if it weakens it.

Benzodiazepines are the textbook example: they do not activate GABA receptors themselves, they make the receptor respond more strongly to the GABA the brain is already producing. The 2018 binding study places Selank in the same category, using radioactively labeled GABA to measure how much binds to brain cell membranes with and without Selank present.

That study reports something else worth noting, because it complicates rather than simplifies: Selank blocked the modulatory activity of diazepam and of olanzapine. A compound that enhances GABA binding on its own and interferes with two established drugs at the same system is not a simple benzodiazepine mimic.

The gene-expression pair, and why they disagree

The 2016 study injected rats with Selank or with GABA itself and measured 84 genes involved in neurotransmission in the frontal cortex at one hour and three hours. Forty-five genes changed at one hour. The changes produced by Selank and by GABA correlated positively with each other — which is the finding that supports the GABAergic story, since the peptide’s fingerprint resembled GABA’s.

The 2017 study asked the same question in a dish. IMR-32 cells are a human neuroblastoma line used to study neuronal biology. The same 84-gene panel was run with Selank, with GABA, with the antipsychotic olanzapine, and with combinations.

Selank alone did nothing measurable to the genes. The authors say so directly, twice — in the results and in the conclusion: “Selank has no direct effect on the mRNA levels of the GABAergic system genes in neuroblastoma IMR-32 cells.”

But the combinations moved. GABA alone changed expression; GABA plus Selank suppressed nearly all of those changes. Olanzapine alone changed expression; olanzapine plus Selank changed more genes than olanzapine by itself.

Read together, the two studies point at something more specific than “Selank is GABAergic”: Selank may do little on its own to these cells and act instead by changing how the cells respond to something else — which fits an allosteric modulator, and which would also explain why an intact animal, full of its own GABA, shows changes that an isolated cell line does not.

That reading is a hypothesis, not a finding. What is established is the pair of results, and the fact that the group published the null alongside the positive.

The other mechanism line: enkephalin-degrading enzymes

Running alongside the GABA work is a separate and older line of Russian research on enkephalins — the body’s own opioid-like peptides — and the enzymes that break them down. A 2001 paper’s title states the hypothesis directly: the inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.

The same measurement appears in the clinical work: the 2008 trial measured serum enkephalin activity in patients alongside the psychometric scales. It is unusual for a clinical trial in this field to carry a mechanistic biomarker, and it is one of the more scientifically serious features of this literature.

Two proposed mechanisms, neither settled, both with published support. That is the accurate state of things.

What the research does not show

The GABAergic mechanism has not been established. The strongest single experiment in human cells found no direct effect on the genes in question.

Nothing here shows Selank binds the benzodiazepine site, or any specific site. The binding study measures an effect on GABA binding; it does not localize where Selank sits.

The gene-expression studies measure messenger RNA, which is a step removed from protein and several steps removed from behavior. A change in expression is a lead, not a mechanism.

And the two studies that disagree share authors and methods, so this is not one group’s finding contradicted by another’s. It is a single research program reporting a result and its own non-replication in a different system — which is more honest than most literatures manage, and a reason to trust the pair more, not less.

Frequently asked questions

Does Selank work like a benzodiazepine?

Its behavioral profile in rodents resembles one, and a binding study describes it as a positive allosteric modulator of GABA binding. But it also blocked diazepam’s modulatory activity in that same study, and it produced no direct gene-expression effect in human cells.

Is Selank addictive?

No study in the retrieved record tests dependence liability for Selank. The withdrawal research is about Selank’s effect on withdrawal from other substances — see our stress and withdrawal page.

Why did the human cell study find nothing?

The published data does not answer that. One possibility consistent with both papers is that Selank acts by modifying responses to other signals rather than by acting alone, which a single-agent test in isolated cells would not detect.

What about the immune side of the mechanism?

That is a separate literature with its own surprises, including a result suggesting a three-residue fragment does much of what the whole peptide does. See our immune and cytokine research page.

References

1. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Protein Pept Lett. 2018. PMID 30255741.
2. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. Front Pharmacol. 2016. PMID 26924987.
3. Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, et al. Front Pharmacol. 2017. PMID 28293190.
4. Zozulya AA, et al. Bull Exp Biol Med. 2001. PMID 11550013.
5. Zozulya AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18454096.

Methodology: quotations are verbatim from the published abstracts of the cited studies, retrieved through NCBI E-utilities on August 28, 2026. Where two studies from the same group disagree, both are reported with their experimental system named.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.